Reaction

Rectal Abscess reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,661 reports · 32 co-occurring drugs

As of the last recalculation, Rectal Abscess appears in 1,661 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 42.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Infliximab-Dyyb9342.242.3
Mesna Injection1929.129.2
Mesna1928.628.7
Ciprofloxacin Hydrochloride And Hydrocortisone4326.626.6
Vedolizumab16125.825.9
Mesalamine8820.720.7
Metronidazole9920.620.6
Mercaptopurine2518.318.4
Trimethoprim1516.116.1
Azathioprine10315.615.6
Ustekinumab11615.215.2
Eplerenone1514.814.8
Infliximab22414.714.7
Ciprofloxacin9914.314.3
Ciprofloxacin Hydrochloride10414.214.2
Diphenoxylate Hydrochloride And Atropine Sulfate1412.912.9
Isotretinoin4511.711.7
Metronidazole Topical4211.311.3
Loperamide Hydrochloride And Dimethicone249.59.5
Leucovorin Calcium149.29.3
Dextrose98.68.6
Dextrose Monohydrate98.58.5
Bupivacaine68.18.1
Certolizumab Pegol697.77.7
Adalimumab3517.67.6
Sevoflurane57.67.6
Irinotecan Hydrochloride65.95.9
Canagliflozin135.55.5
Erlotinib45.25.2
Daratumumab165.15.1
Risankizumab-Rzaa325.05.0
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride72.82.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.